Higher inflation, stubbornly high rates and volatile energy prices are pushing many investors to look beyond crowded trades and seek focused, research-driven themes.

One area drawing attention is neuroscience, where a group of lesser known biotechs is working on Parkinson’s disease treatments while still flying under most radars. The Under the Radar Parkinson’s Biotech Stocks screener filters this space for stocks where analyst targets currently imply meaningful valuation upside.

In this article, you will see three stocks from that screener and get a clear, plain English breakdown of why each one might deserve a closer look.

Gain Therapeutics (Nasdaq:GANX)

Overview: Gain Therapeutics is a Bethesda-based biotech using its Magellan discovery platform to find small molecules that adjust how disease related proteins work, led by GT-02287, an oral GCase modulator now in a Phase 1b study for Parkinson’s disease and supported by earlier stage programs in dementia, Alzheimer’s and rare metabolic disorders.

Market Cap: US$74.6 million

Gain Therapeutics sits at the speculative end of this Parkinson’s screener, pairing eye catching Phase 1b signals in GT-02287, including biomarker reductions and motor score improvements presented at AD/PD 2026, with a balance sheet flagged by auditors for going concern risk and less than one year of cash runway. The company has no revenue and ongoing losses, and shareholders have already absorbed substantial dilution. At the same time, it retains full global rights to its lead asset, has grant backing from respected foundations and trades on a modest market value versus peers working on the same GCase pathway. For investors who can tolerate volatility and financing risk, the mix of early efficacy signals, a broader lysosomal pipeline and a low starting valuation may merit further research once the fuller risk profile is understood.

GT-02287’s early signals and a modest market value could be masking a much bigger story for Gain Therapeutics, and the full narrative for Gain Therapeutics may reveal one risk and catalyst investors aren’t fully pricing in yet.

Annovis Bio (NYSE:ANVS)

Overview: Annovis Bio is a clinical-stage biotech company based in Malvern, Pennsylvania, focused on developing drug candidates like buntanetap to treat neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, traumatic brain injury and dementia.

Market Cap: US$74.5 million

For investors screening Parkinson’s stocks, Annovis Bio sits at the high risk, high potential end of the spectrum. It trades at a deep discount to an internal fair value model and analyst targets that sit above the current share price. However, it also has a history of losses, going concern uncertainty and heavy reliance on external funding. The recent Nature NPJ Dementia paper on buntanetap, showing safety, dose related cognitive benefits in biomarker positive mild Alzheimer’s and encouraging biomarker trends, adds scientific support behind a pivotal phase 3 program that could be significant if successful. At the same time, share price volatility, shareholder dilution and an expensive P/B relative to peers show that sentiment can swing sharply. This is why the full risk reward profile matters here.

Analysts see room between Annovis Bio’s current share price and their targets, but that gap only matters if the science holds up. Get the full story in the 1 key reward and 4 important warning signs (2 are major!).

Clene (Nasdaq:CLNN)

Overview: Clene is a clinical-stage pharma company based in Salt Lake City that is developing clean surfaced nanotechnology drugs, led by CNM-Au8 for ALS, multiple sclerosis and Parkinson’s, while also advancing silver and zinc based candidates for infectious diseases and selling related metal based dietary supplements.

Market Cap: US$87.0 million

Clene sits in the high growth, high risk corner of this screener, with forecasts for rapid earnings and revenue growth tied to its CNM-Au8 program and a recent FDA readout indicating the data package may support an accelerated approval filing for ALS. At the same time, the company reported very low current revenue, widening losses of US$8.09m in Q1 2026, negative equity and an auditor warning for a going concern, all alongside insider selling and fresh equity offerings. Investors willing to consider distressed balance sheets in exchange for potential upside from a pivotal regulatory catalyst and seasoned management oversight may find this a situation that warrants closer examination of the underlying details.

Accelerating drug timelines and an FDA window for CNM-Au8 could be masking one crucial tension in Clene’s story. See how the analyst forecasts for Clene stack up against its distressed balance sheet and what that contrast may be hinting at next.

The three Parkinson’s stocks covered here are just a starting point, and the full Under-the-Radar Parkinson's Biotech Stocks screener uncovered three more companies with equally compelling risk reward narratives and scientific angles. Use Simply Wall St to identify and analyze the exact catalysts, balance sheet markers and valuation gaps that matter to you. This can help you focus on the opportunities that best fit your highest conviction ideas.

Take Control of Your Investment Journey

If Gain Therapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Your Watchlist?

Markets move fast and the best breakout setups rarely stay under the radar for long. Scan fresh ideas before momentum is fully caught and entries start dropping, act now.

1. Spot companies with strong balance sheets and steady fundamentals by running the list of solid balance sheet and fundamentals (46 results) to find candidates that can handle shocks while others are still reacting.
2. Explore compounding income potential with the 12 dividend fortresses to focus on companies offering high yields that could reward patience while prices are still settling.
3. Track major infrastructure themes with the 35 power grid technology and infrastructure stocks and follow businesses positioned for long term grid upgrades while the story is still building.

Simply Wall St analyst Bailey and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.